Ovarian cancer is one of the malignant tumors that seriously threaten women's health. The incidence rate ranks third among malignant tumors of female reproductive system, and the mortality rate ranks first among gynecological malignant tumors. Ovarian cancer is an insidious onset.  Due to the lack of effective screening and early diagnosis measures, the vast majority of patients have local or distant spread at the time of diagnosis, and the 5-year survival rate is about 46%. Therefore, it is necessary to deeply explore the functions of related genes in ovarian cancer and develop targeted drugs for treatment. To this end, we provide an in vivo delivery system targeting ovarian cancer cells for in vivo studies of related gene functions.

Target Genes Delivered In Vivo in Ovarian Cancer

Most ovarian cancers are sporadic, and hereditary ovarian cancers account for about 15% of all ovarian cancers. At present, germline mutations of more than ten tumor suppressor genes have been found to be associated with hereditary ovarian cancer, and more than 80% of hereditary ovarian cancers are related to BRCA1/2 germline mutations. Genes with germline mutations that increase the risk of epithelial ovarian cancer include BRCA1/2, RAD51C, RAD51D, BRIP1, PALB2, ATM, and Lynch syndrome-related genes (MLH1, MSH2, MSH6, PMS2, EPCAM).

In addition, CA125, human epididymal protein 4 (HE4), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9), alpha-fetoprotein (AFP), β-human Chorionic gonadotropin (β-hCG), estradiol (E2), progesterone, squamous cell carcinoma antigen (SCCA), neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and other genes are also Both were found to be abnormally expressed in ovarian cancer cells. Therefore, these could also serve as potential targets for further research to develop into drugs.

Figure 1. Schematic overview of susceptibility genes for familial ovarian cancer. (Varga D, et al.; 2013)

In addition to the above genes, there are interesting ovarian cancer-related genes that need to be explored and studied. Therefore, there is a need for an in vivo transfection system that can precisely target ovarian cancer tissue and be taken up by tumor cells to function in vivo. The system can help researchers overcome various challenges encountered during in vivo transfection:

• Relevant molecular function studies can only be carried out in vitro, lacking important in vivo data
• Using in vitro transfection system for in vivo transfection, the transfection efficiency is very low;
• The in vivo transfection system used is not specific to ovarian cancer tissues and cells, and is toxic to the body;
• The in vivo transfection system used cannot penetrate the ovarian cancer tissue into the tumor tissue;
• The nucleic acid load of the in vivo transfection system is low, and it is difficult to achieve the expected effect;
• Etc…

Our Advantage:

• We can provide an in vivo transfection system for ovarian cancer tissues and cells to achieve efficient transfection
• Our system can target multiple targets at the same time, improving targeting accuracy
• The in vivo transfection system has low toxicity to the body and is safe to use
• In vivo transfection system vectors can protect nucleic acids from degradation during in vivo delivery
• Persistent knockout effect in experimental animals after a single injection
• The system load is high, and the transfection needs of different doses can be completed
• Professional design and service team to provide you with reliable service and technical support
• Timely feedback of technical reports

CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect in vivo transfection system, you can contact us. We can provide one-to-one personal customization service.

References

1. MAVADDAT N, et al.; Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013, 105(11): 812-822.
2. WRIGHT J D, et al.; Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009, 115(18): 4118-4126.
3. GERSHENSON D M. Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. Gynecol Oncol. 2012, 125(3): 515-517.
4. AL HARBI R, et al.; Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. Int J Gynecol Cancer. 2021,31(2): 161-168.
5. Varga D, et al.; Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci. 2013, 14(1):640-73.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.